ATTO-1310 / Attovia Therap - LARVOL DELTA

SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF ATTO-1310, A NOVEL ANTI-IL31 ATTOBODY-FC FUSION PROTEIN, IN HEALTHY ADULTS (EADV 2026) - "Conclusions ATTO-1310 was well tolerated in healthy adults with no serious or severe treatment-related TEAEs and a low incidence of ADAs. Single and multiple SC administration of ATTO-1310 in healthy adults resulted in rapid and sustained reduction of percent free IL-31 extending up to 12 weeks."

Clinical • First-in-human • PK/PD data • Atopic Dermatitis • Dermatitis • Immunology • Inflammation • Prurigo Nodularis • Pruritus • CD123 • IL31RA

Efficacy and Safety of ATTO-1310 in the Treatment of Participants With Chronic Pruritus of Unknown Origin (clinicaltrials.gov) - P2 | N=300 | Not yet recruiting | Sponsor: Attovia Therapeutics Inc

New P2 trial • Dermatology • Pruritus

Safety, Tolerability and PK of ATTO-1310 in Healthy Volunteers and Patients With Atopic Dermatitis and Patients With Chronic Pruritus (clinicaltrials.gov) - P1 | N=108 | Completed | Sponsor: Attovia Therapeutics Inc | Active, not recruiting ➔ Completed

Trial completion • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Pruritus

Safety, Tolerability and PK of ATTO-1310 in Healthy Volunteers and Patients With Atopic Dermatitis and Patients With Chronic Pruritus (clinicaltrials.gov) - P1 | N=108 | Active, not recruiting | Sponsor: Attovia Therapeutics Inc | Recruiting ➔ Active, not recruiting

Enrollment closed • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Pruritus

Attovia Therapeutics Announces $90 Million Series C Financing to Advance ATTOBODY-based Programs through Clinical Proof of Concept (GlobeNewswire) - "Attovia Therapeutics...today announced the close of a $90 million Series C financing....Proceeds from the financing, along with the Company’s existing cash and investments, will be used to advance Attovia’s lead assets, ATTO-1310 and ATTO-3712, through clinical proof-of-concept, with the aim of achieving best-in-disease efficacy for the treatment of chronic pruritus and atopic dermatitis....The company plans to start Phase 1 clinical studies with ATTO-3712 in the second half of 2025."

Financing • New P1 trial • Atopic Dermatitis • Pruritus

Safety, Tolerability and PK of ATTO-1310 in Healthy Volunteers and Patients with Atopic Dermatitis and Patients with Chronic Pruritus (clinicaltrials.gov) - P1 | N=104 | Recruiting | Sponsor: Attovia Therapeutics Inc | N=80 ➔ 104

Enrollment change • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Pruritus

Attovia Therapeutics Announces First Participant Dosed in First-in-Human Phase 1 Study of ATTO-1310, its Novel Half-life Extended Anti-IL-31 ATTOBODY for the Treatment of Chronic Pruritus (GlobeNewswire) - "Attovia Therapeutics...today announced that the first subject has been dosed in a first-in-human Phase 1 study of ATTO-1310....The Phase 1 study...is a randomized, double-blind, placebo-controlled, multi-part, single-ascending dose and multiple-ascending dose study to assess the safety, tolerability, and pharmacokinetics of ATTO-1310 in healthy adult volunteers and patients suffering from pruritic disease."

Trial status • Immunology

Safety, Tolerability and PK of ATTO-1310 in Healthy Volunteers and Patients with Atopic Dermatitis (clinicaltrials.gov) - P1 | N=80 | Recruiting | Sponsor: Attovia Therapeutics Inc

New P1 trial • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

ATTO-1310: A first-in-class anti-IL31 Attobody® for atopic dermatitis and other pruritic diseases (EADV 2024) - "Nemolizumab, which binds IL31RA, has shown promising anti-pruritic efficacy in clinical trials, providing validation that targeting the IL31 pathway translates to symptom relief in AD and PN patients. Nonclinical efficacy and PK data to date support advancement of ATTO-1310 to first-in-human clinical studies."

Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Prurigo Nodularis • Pruritus • CD123 • IL1R1 • IL31RA

Attovia Therapeutics Raises $105 Million Oversubscribed Series B Financing Led by Goldman Sachs Alternatives (GlobeNewswire) - "Attovia Therapeutics today announced the closing of a $105 million oversubscribed Series B financing, bringing the total capital raised by the Company since its launch in June 2023 to $165 million. Proceeds from the financing will be used to advance the Company’s lead programs ATTO-1310 and ATTO-002 through initial clinical data readouts, expand the Company’s immunology and inflammation pipeline, and to further develop the ATTOBODY platform....Attovia expects to nominate a development candidate for ATTO-002 in the second half of 2024 and advance the candidate to IND in 2025."

Financing • Pipeline update • Atopic Dermatitis • Immunology